Fecal microbiota transplantation for managing irritable bowel syndrome

El‐Salhy, Magdy; Mazzawi, Tarek

doi:10.1080/17474124.2018.1447380

Cited by 64 publications

(72 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Halvorson et al reported a seven-fold increased risk of post-infectious IBS after acute infectious gastroenteritis [34]. Moreover, therapeutic interventions that manipulate the gut microbiota such as antibiotics, prebiotics, probiotics, and fecal microbial transplantation have been linked to improvements in IBS symptoms [35][36][37]. Several studies aiming to characterize and map the microbiome signature of IBS have shown divergent results.…”

Section: The Microbiome In Ibsmentioning

confidence: 99%

The Evolving Role of Gut Microbiota in the Management of Irritable Bowel Syndrome: An Overview of the Current Knowledge

Mari

Baker

Mahamid

et al. 2020

JCM

View full text Add to dashboard Cite

The intestinal microbiota is one of the most rapidly evolving areas in biology and medicine. Extensive research in the last decade has escalated our understanding of the role of the microbiota in the pathogenesis of several intestinal and extra-intestinal disorders. Marked by high prevalence, substantial morbidity, and enormous costs, irritable bowel syndrome (IBS) is an important chronic gastrointestinal disorder that is widely encountered by gastroenterologists. Despite advances in our understanding of its pathophysiology, curative interventions have yet to be discovered, and therapeutic approaches remain symptom-driven. Recently, accumulating evidence has enlightened the possible impact of an imbalanced gut microbiome in the pathogenesis of IBS. In fact, several studies have documented altered microbiota in patients, while others have shown that IBS severity was associated with a distinct microbiota signature. These findings may pave the way for the use of microbiota manipulation strategies as an attractive option for IBS management, and may have an essential role in efforts to reduce the societal and economic effects of this ever-growing disorder. In this review, we have outlined the results of the latest research on the association between microbiota and IBS and their implications for the clinical management of affected patients.

show abstract

Section: The Microbiome In Ibsmentioning

confidence: 99%

The Evolving Role of Gut Microbiota in the Management of Irritable Bowel Syndrome: An Overview of the Current Knowledge

Mari

Baker

Mahamid

et al. 2020

JCM

View full text Add to dashboard Cite

show abstract

“…Faecal microbiota transplantation (FMT) is capable of contributing nutrients, inhibiting the growth of pathogenic bacteria and regulating the immune system of the host through transplanting functional bacteria from healthy individuals into the gastrointestinal tract of patients, thereby helping patients reconstruct the normal functions of the gut microbiota . FMT is effective in treating recurrent Clostridium difficile infection, inflammatory bowel disease and irritable bowel syndrome . However, the potential for treating CVD needs further investigation.…”

Section: Therapeutics Based On the Microbiotamentioning

confidence: 99%

“…81 FMT is effective in treating recurrent Clostridium difficile infection, 82 inflammatory bowel disease 83 and irritable bowel syndrome. 84 However, the potential for treating CVD needs further investigation.…”

Section: Faecal Microbiota Transplantationmentioning

confidence: 99%

The role of intestinal microbiota in cardiovascular disease

Jin

Qian

Yin

et al. 2019

J Cellular Molecular Medi

171

113

View full text Add to dashboard Cite

Accumulating evidence has indicated that intestinal microbiota is involved in the development of various human diseases, including cardiovascular diseases (CVDs). In the recent years, both human and animal experiments have revealed that alterations in the composition and function of intestinal flora, recognized as gut microflora dysbiosis, can accelerate the progression of CVDs. Moreover, intestinal flora metabolizes the diet ingested by the host into a series of metabolites, including trimethylamine N‐oxide, short chain fatty acids, secondary bile acid and indoxyl sulfate, which affects the host physiological processes by activation of numerous signalling pathways. The aim of this review was to summarize the role of gut microbiota in the pathogenesis of CVDs, including coronary artery disease, hypertension and heart failure, which may provide valuable insights into potential therapeutic strategies for CVD that involve interfering with the composition, function and metabolites of the intestinal flora.

show abstract

“…The treatment of refractory type II CD is very difficult, it's worth noting that the symptoms of CD disappear completely, and duodenal villi are completely recovered when treated with FMT. In addition, there are also some potential indications for FMT are IBS (El‐Salhy and Mazzawi 2018) and CC (Ohkusa et al . 2019).…”

Section: Treatment and Adjustmentmentioning

confidence: 99%

Gut dysbacteriosis and intestinal disease: mechanism and treatment

Meng

Zhang

Cao³

et al. 2020

J. Appl. Microbiol.

View full text Add to dashboard Cite

Summary The gut microbiome functions like an endocrine organ, generating bioactive metabolites, enzymes or small molecules that can impact host physiology. Gut dysbacteriosis is associated with many intestinal diseases including (but not limited to) inflammatory bowel disease, primary sclerosing cholangitis‐IBD, irritable bowel syndrome, chronic constipation, osmotic diarrhoea and colorectal cancer. The potential pathogenic mechanism of gut dysbacteriosis associated with intestinal diseases includes the alteration of composition of gut microbiota as well as the gut microbiota–derived signalling molecules. The many correlations between the latter and the susceptibility for intestinal diseases has placed a spotlight on the gut microbiome as a potential novel target for therapeutics. Currently, faecal microbial transplantation, dietary interventions, use of probiotics, prebiotics and drugs are the major therapeutic tools utilized to impact dysbacteriosis and associated intestinal diseases. In this review, we systematically summarized the role of intestinal microbiome in the occurrence and development of intestinal diseases. The potential mechanism of the complex interplay between gut dysbacteriosis and intestinal diseases, and the treatment methods are also highlighted.

show abstract

Fecal microbiota transplantation for managing irritable bowel syndrome

Cited by 64 publications

References 79 publications

The Evolving Role of Gut Microbiota in the Management of Irritable Bowel Syndrome: An Overview of the Current Knowledge

The Evolving Role of Gut Microbiota in the Management of Irritable Bowel Syndrome: An Overview of the Current Knowledge

The role of intestinal microbiota in cardiovascular disease

Gut dysbacteriosis and intestinal disease: mechanism and treatment

Contact Info

Product

Resources

About